S. Vallabhajosula

发表

Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task.

Philip D. Harvey, M. Buchsbaum, L. Shihabuddin, 1998, Archives of general psychiatry.

Radiotracers for low density lipoprotein biodistribution studies in vivo: technetium-99m low density lipoprotein versus radioiodinated low density lipoprotein preparations.

V. Fuster, S. Vallabhajosula, J. Badimón, 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Possible axonal regrowth in late recovery from the minimally conscious state.

Bruce D. McCandliss, N. Schiff, H. Voss, 2006, The Journal of clinical investigation.

Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood. Effects of different stenoses on thrombus growth.

S. Vallabhajosula, L. Badimón, R. Lassila, 1990, Arteriosclerosis.

Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery

M. D. de Leon, S. Vallabhajosula, L. Mosconi, 2017, PloS one.

Correction: Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery

M. D. de Leon, S. Vallabhajosula, L. Mosconi, 2018, PloS one.

Increased fibrillar amyloid-β burden in normal individuals with a family history of late-onset Alzheimer’s

S. de Santi, M. D. de Leon, S. Vallabhajosula, 2010, Proceedings of the National Academy of Sciences.

Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD

M. D. de Leon, S. Vallabhajosula, L. Mosconi, 2014, Neurology.

Associations of lifestyle and vascular risk factors with Alzheimer’s brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City area

M. D. de Leon, S. Vallabhajosula, L. Mosconi, 2018, BMJ Open.

Periodontal disease associates with higher brain amyloid load in normal elderly

M. Leon, H. Rusinek, S. Vallabhajosula, 2015, Neurobiology of Aging.

Physical Activity, Mediterranean Diet and Biomarkers-Assessed Risk of Alzheimer’s: A Multi-Modality Brain Imaging Study

M. D. de Leon, S. Vallabhajosula, L. Mosconi, 2014, Advances in molecular imaging.

Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.

S. Vallabhajosula, N. Bander, S. Tagawa, 2016, Current radiopharmaceuticals.

Noninvasive PK11195‐PET Image Analysis Techniques Can Detect Abnormal Cerebral Microglial Activation in Parkinson's Disease

Jenna M. Sullivan, P. Mozley, S. Vallabhajosula, 2018, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[11C]arachidonic acid incorporation measurement in human brain: Optimization for clinical use

P. Mozley, J. Mann, S. Rapoport, 2018, Synapse.

Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults

Alberto Pupi, Shankar Vallabhajosula, Lisa Mosconi, 2018, Neurology.

Nutrient patterns and brain biomarkers of Alzheimer’s disease in cognitively normal individuals

Alberto Pupi, Shankar Vallabhajosula, Lisa Mosconi, 2015, The journal of nutrition, health & aging.

Validation in the canine model of a new non-invasive method of measuring coronary blood flow reserve: Split dose thallium-201 rest/stress imaging

J. Machac, S. Vallabhajosula, M. Henzlova, 2001, The International Journal of Cardiovascular Imaging.

A new iterative reconstruction technique for attenuation correction in high-resolution positron emission tomography

M. Buchsbaum, J. Machac, K. Knešaurek, 1996, European Journal of Nuclear Medicine.

Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer

H. Beltran, S. Vallabhajosula, N. Bander, 2019, Cancer.

Noninvasive imaging of 99mtechnetium-labeled low density lipoprotein uptake by tendon xanthomas in hypercholesterolemic patients.

S. Vallabhajosula, H. Ginsberg, S. Goldsmith, 1990, Arteriosclerosis.

Site-specific (18)F-labeling of the protein hormone leptin using a general two-step ligation procedure.

T. Muir, S. Vallabhajosula, J. Friedman, 2008, Journal of the American Chemical Society.

67Ga-transferrin and 67Ga-lactoferrin binding to tumor cells: Specific versus nonspecific glycoprotein-cell interaction

S. Vallabhajosula, S. Goldsmith, T. Ohnuma, 2004, European Journal of Nuclear Medicine.

Investigation of the role of the base in the synthesis of [18F]FLT.

S. Vallabhajosula, D. Ballon, S. Goldsmith, 2007, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Radionuclide diagnosis of vertebral osteomyelitis: indium-111-leukocyte and technetium-99m-methylene diphosphonate bone scintigraphy.

S. Vallabhajosula, S. Goldsmith, C. Palestro, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Effect of blood-brain barrier and blood-tumor barrier modification on central nervous system liposomal uptake.

S. Vallabhajosula, R. Zappulla, S. Goldsmith, 1993, Cancer investigation.

Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

S. Vallabhajosula, N. Bander, K. Hamacher, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

Stanley J. Goldsmith, Shankar Vallabhajosula, Howard I. Scher, 2013, Clinical Cancer Research.

Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer.

S. Vallabhajosula, N. Bander, J. Osborne, 2020, The oncologist.

Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer

S. Vallabhajosula, N. Bander, B. Robinson, 2013, Front. Oncol..

Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?

S. Vallabhajosula, N. Bander, K. Hamacher, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC)

S. Vallabhajosula, N. Bander, M. Morris, 2008 .

Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC).

S. Vallabhajosula, N. Bander, S. Tagawa, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose-escalation study of docetaxel/predisone and fractionated 177Lu-J591 for metastatic castrate-resistant prostate cancer (metCRPC).

H. Beltran, S. Vallabhajosula, N. Bander, 2010 .

A randomized phase II trial of 177lu radiolabeled monoclonal antibody J591 (177Lu-J591) and ketoconazole in patients (pts) with high-risk castrate biochemically relapsed prostate cancer (PC) after local therapy.

H. Beltran, S. Vallabhajosula, J. Osborne, 2010 .

Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC).

H. Beltran, S. Vallabhajosula, N. Bander, 2010 .

952 ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)-BASED RADIOIMMUNOTHERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A DECADE OF EXPERIENCE WITH RADIOLABELED (RL)-J591

H. Beltran, S. Vallabhajosula, N. Bander, 2012 .

Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides.

S. Vallabhajosula, B. Moyer, R. Dean, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.

S. Vallabhajosula, N. Bander, M. Milowsky, 2006, Clinical genitourinary cancer.

Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma

J. Leonard, S. Vallabhajosula, L. Kostakoglu, 2002, Cancer.

Metastatic Human Colonic Carcinoma: Molecular Imaging with PretargetedSPECTandPETina

S. Vallabhajosula, W. Mcbride, D. Goldenberg, 2008 .

Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.

S. Vallabhajosula, W. Mcbride, D. Goldenberg, 2008, Radiology.

Low-density lipoprotein (LDL) distribution shown by 99mtechnetium-LDL imaging in patients with myeloproliferative diseases.

S. Vallabhajosula, H. Ginsberg, M. Paidi, 1989, Annals of internal medicine.

Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer

Larson, S. Vallabhajosula, N. Bander, 2013 .

A combined clinical/computer model for the study of myocardial thallium-201 washout/reinjection kinetics

J. Machac, S. Vallabhajosula, M. K. Ali, 1994, Computers in Cardiology 1994.

Non-specific binding of transferrin and lactoferrin to polystyrene culture tubes: Role of the radioligand

S. Vallabhajosula, S. Goldsmith, 2004, European Journal of Nuclear Medicine.

Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.

S. Vallabhajosula, N. Bander, S. Goldsmith, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice

S. Vallabhajosula, N. Bander, S. Goldsmith, 2004, The Prostate.

Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer

S. Vallabhajosula, N. Bander, M. Milowsky, 2005 .

Indium-111 platelet kinetics in normal human subjects: tropolone versus oxine methods.

V. Fuster, J. Machac, S. Vallabhajosula, 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Molecular Imaging: Radiopharmaceuticals for PET and SPECT

S. Vallabhajosula, 2009 .

Value of blood-pool subtraction in cardiac indium-111-labeled platelet imaging.

V. Fuster, J. Machac, S. Vallabhajosula, 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Peptides in Biomedical Sciences: Principles and Practice

S. Vallabhajosula, R. Lees, A. M. Lees, 1994 .

Early assessment of radiation response using a novel functional imaging modality -- [18F]fluorocholine PET (FCH-PET): a pilot study.

S. Vallabhajosula, K. Chao, J. Osborne, 2012, Discovery medicine.

Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity

S. Vallabhajosula, N. Bander, L. Kostakoglu, 2005, Clinical Cancer Research.

Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

S. Vallabhajosula, N. Bander, C. Sternberg, 2020 .

Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

S. Vallabhajosula, N. Bander, C. Sternberg, 2020 .

Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

H. Beltran, S. Vallabhajosula, N. Bander, 2019, Annals of Oncology.

Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).

H. Beltran, S. Vallabhajosula, N. Bander, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).

H. Beltran, S. Vallabhajosula, N. Bander, 2014 .

Intrathecal 99mTc‐DTPA imaging of molecular passage from lumbar cerebrospinal fluid to brain and periphery in humans

P. Mozley, S. Vallabhajosula, L. Horky, 2020, Alzheimer's & dementia.

A pilot study treatment of malignant tumors using low-dose 18F-fluorodeoxyglucose (18F-FDG).

S. Vallabhajosula, C. Palestro, E. K. Fung, 2020, American journal of nuclear medicine and molecular imaging.

Technetium-99m-white blood cell-specific imaging agent developed from platelet factor 4 to detect infection.

S. Vallabhajosula, L. Bush, B. Moyer, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radioiodinated Capsids Facilitate In Vivo Non-Invasive Tracking of Adeno-Associated Gene Transfer Vectors

H. Voss, S. Vallabhajosula, D. Ballon, 2017, Scientific Reports.

Technetium-99m-labeled chemotactic peptides: specific for imaging infection?

S. Vallabhajosula, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Continuation of comprehensive quality control of the itG 68Ge/68Ga generator and production of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for clinical research studies.

James M. Kelly, S. Vallabhajosula, J. Babich, 2017, Nuclear medicine and biology.

Subsequent therapy can be administered after tositumomab and iodine I‐131 tositumomab for non‐Hodgkin lymphoma

J. Leonard, S. Vallabhajosula, L. Kostakoglu, 2006, Cancer.

Chemistry and biological behavior of samarium-153 and rhenium-186-labeled hydroxyapatite particles: potential radiopharmaceuticals for radiation synovectomy.

S. Vallabhajosula, S. Goldsmith, A. Tofe, 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Targeted Radionuclide Therapy of Prostate Cancer

S. Vallabhajosula, N. Bander, S. Tagawa, 2013 .

PET and SPECT Scanners

S. Vallabhajosula, 2009 .

Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method?

S. Vallabhajosula, N. Bander, K. Hamacher, 2004, Cancer Biotherapy and Radiopharmaceuticals.

177Lu‐DOTA‐HuJ591: A new radiolabeled monoclonal antibody (MAb) for targeted therapy of prostate cancer

S. Vallabhajosula, N. Bander, S. Goldsmith, 2001 .

Radioimmunotherapy of Prostate Carcinoma

S. Vallabhajosula, N. Bander, S. Tagawa, 2013 .

A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?

S. Vallabhajosula, L. Solnes, B. Vallabhajosula, 2011, Seminars in nuclear medicine.

Guest Editorial: new PET radiopharmaceuticals as molecular imaging probes.

S. Vallabhajosula, 2011, Seminars in nuclear medicine.

Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate.

S. Vallabhajosula, J. Holland, B. Kamen, 1989, Cancer research.

The utility of monoclonal antibodies in the imaging of prostate cancer.

S. Vallabhajosula, M. Milowsky, L. Kostakoglu, 2002, Seminars in urologic oncology.

PET studies in psychiatry: validity, accuracy and future.

S. Vallabhajosula, M. Buchsbaum, 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

H. Beltran, S. Vallabhajosula, N. Bander, 2018 .

(18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.

Shankar Vallabhajosula, S. Vallabhajosula, 2007, Seminars in nuclear medicine.

In vivo stability of ferric hydroxide macroaggregates (FHMA). Is it a suitable carrier for radionuclides used in synovectomy?

S. Vallabhajosula, S. Goldsmith, M. Chinol, 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Platelet thrombus formation on collagen type I. A model of deep vessel injury. Influence of blood rheology, von Willebrand factor, and blood coagulation.

V. Fuster, S. Vallabhajosula, L. Badimón, 1988, Circulation.

Odor Identification Ability Predicts PET Amyloid Status and Memory Decline in Older Adults.

D. Devanand, G. Pradhaban, G. Pelton, 2018, Journal of Alzheimer's disease : JAD.

Basis of Radiopharmaceutical Localization

S. Vallabhajosula, A. Owunwanne, 2015 .

Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology.

S. Vallabhajosula, A. Nikolopoulou, 2011, Seminars in nuclear medicine.

Pathophysiology and Mechanisms of Radiopharmaceutical Localization

S. Vallabhajosula, A. Owunwanne, 2006 .

Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.

T. Schwartz, S. Vallabhajosula, P. Stieg, 2011, Journal of neurosurgery.

Detection of abnormalities in febrile AIDS patients with In-111-labeled leukocyte and Ga-67 scintigraphy.

S. Vallabhajosula, S. Goldsmith, C. Palestro, 1989, Radiology.

Clinically proven radiopharmaceuticals for infection imaging: mechanisms and applications.

S. Vallabhajosula, S. Goldsmith, 2009, Seminars in nuclear medicine.

Scintigraphic evaluation of Tc‐99m‐low‐density lipoprotein (LDL) distribution in patients with Gaucher disease

S. Vallabhajosula, G. Pastores, M. Lorberboym, 1997, Clinical genetics.

99mTc-low density lipoprotein: intracellularly trapped radiotracer for noninvasive imaging of low density lipoprotein metabolism in vivo.

S J Goldsmith, S. Vallabhajosula, S. Goldsmith, 1990, Seminars in nuclear medicine.

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

A. D. Van den Abbeele, A. LaCasce, M. Millenson, 2012, Blood.

RAD1OCHEMISTRY AND RADIOPHARMACEU11CALS RadiochemicalAnalysisof Tc-99m HumanSerumAlbuminwith High-Pressure LiquidChromatography:ConciseCommunication

S. Vallabhajosula, S. Goldsmith, R. Pollina, 2006 .

Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors.

S. Vallabhajosula, J. Osborne, R. Killeen, 2010, Seminars in nuclear medicine.

PET imaging of leptin biodistribution and metabolism in rodents and primates.

T. Muir, S. Vallabhajosula, J. Friedman, 2009, Cell metabolism.

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.

Shankar Vallabhajosula, David M Nanus, Neil H Bander, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.

S. Vallabhajosula, N. Bander, M. Milowsky, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer

William C. Eckelman, James B. Stubbs, Stanley J. Goldsmith, 2013, The Journal of Nuclear Medicine.

Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.

S. Vallabhajosula, N. Bander, M. Milowsky, 2003, The Journal of urology.

PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2.

S. Vallabhajosula, A. Nikolopoulou, M. Figueiredo-Pereira, 2014, Biochimica et biophysica acta.

Parkinson-like neuronal loss and motor de fi cits but not microglia activation induced by prostaglandin J 2

S. Vallabhajosula, A. Nikolopoulou, M. Figueiredo-Pereira, 2014 .

Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets

P. Serrano, S. Vallabhajosula, J. Babich, 2018, Journal of Neuroinflammation.

Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets

S. Vallabhajosula, J. Babich, A. Nikolopoulou, 2018, Journal of Neuroinflammation.

Prostate-specific membrane antigen-based imaging.

Shankar Vallabhajosula, S. Vallabhajosula, K. Deh, 2013, Urologic oncology.

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

S. Vallabhajosula, N. Bander, M. Milowsky, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive Quality Control of the ITG 68Ge/68Ga Generator and Synthesis of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for Clinical Imaging

S. Vallabhajosula, J. Babich, M. Meckel, 2016, The Journal of Nuclear Medicine.

Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.

J. Leonard, E. Cesarman, S. Vallabhajosula, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Platelet Thrombus Formation

V. Fuster, S. Vallabhajosula, J. Badimón, 2005 .

Indium-111-labeled leukocyte scintigraphy in hemodialysis access-site infection.

S. Vallabhajosula, S. Goldsmith, C. Palestro, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

99mTc-MIP-1404 Planar and SPECT scan: Imaging biomarker of androgen receptor (AR) signaling and prostate specific membrane antigen (PSMA) expression.

J. A. Epstein, S. Vallabhajosula, S. Tagawa, 2016 .

Selective CDK 4 / 6 inhibition with tumor responses by PD 0332991 in patients with mantle cell lymphoma *

A. LaCasce, M. Millenson, J. Leonard, 2012 .

Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma

A. LaCasce, J. Leonard, S. Larson, 2008 .

Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer

H. Beltran, S. Vallabhajosula, N. Bander, 2010, Cancer.

Radiochemical analysis of Tc-99m human serum albumin with high-pressure liquid chromatography: concise communication.

S. Vallabhajosula, S. Goldsmith, H. Lipszyc, 1982, Journal of Nuclear Medicine.

Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects.

M G Stabin, S J Goldsmith, S. Vallabhajosula, 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

linically Proven Radiopharmaceuticals for nfection Imaging: Mechanisms and Applications

S. Vallabhajosula, J. Goldsmith, 2022 .

Sex differences in Alzheimer risk

M. D. de Leon, S. Vallabhajosula, L. Mosconi, 2017, Neurology.

Relationships among Cortical Glutathione Levels, Brain Amyloidosis, and Memory in Healthy Older Adults Investigated In Vivo with 1H-MRS and Pittsburgh Compound-B PET

S. Vallabhajosula, R. Isaacson, X. Mao, 2017, American Journal of Neuroradiology.

Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.

Shankar Vallabhajosula, S. Vallabhajosula, 2011, Seminars in nuclear medicine.

Atherosclerosis: imaging techniques and the evolving role of nuclear medicine.

V. Fuster, S. Vallabhajosula, Shankar Vallabhajosula, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radiochemistry and Radiopharmacy

S. Vallabhajosula, A. Verbruggen, S. Guhlke, 2007 .

Studies of the hepatocellular uptake of the hepatobiliary scintiscanning agent 99mTc-DISIDA.

S. Vallabhajosula, S. Goldsmith, P. Berk, 1986, Journal of hepatology.

Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study

M. D. de Leon, S. Vallabhajosula, L. Mosconi, 2018, PloS one.

Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study

Shankar Vallabhajosula, Yi Li, Tracy Butler, 2014, BMJ Open.

FDG and Amyloid PET in Cognitively Normal Individuals at Risk for Late-Onset Alzheimer’s Disease

Yi Li, Shankar Vallabhajosula, Satoshi Minoshima, 2014, Advances in molecular imaging.

Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents

S. Vallabhajosula, L. Mosconi, W. Tsui, 2013, Neurobiology of Aging.

Maternal age affects brain metabolism in adult children of mothers affected by Alzheimer's disease

S. Santi, S. Vallabhajosula, L. Mosconi, 2012, Neurobiology of Aging.

Low density lipoprotein receptor-independent hepatic uptake of a synthetic, cholesterol-scavenging lipoprotein: implications for the treatment of receptor-deficient atherosclerosis.

S. Vallabhajosula, K. Williams, S. Goldsmith, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer.

S. Vallabhajosula, N. Bander, Y. Whang, 2020, Urologic oncology.

Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement

J. Leonard, S. Vallabhajosula, S. Kroll, 2007, Leukemia & lymphoma.

Pre-clinical evaluation of technetium-99m platelet receptor-binding peptide.

J. Machac, S. Vallabhajosula, L. Bush, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.

P. Mozley, S. Vallabhajosula, S. Gauthier, 2017, Multiple sclerosis and related disorders.

The Chemistry of Therapeutic Radiopharmaceuticals

S. Vallabhajosula, 2013 .

Radioimmunotherapy (RIT) Dose-Escalation Studies in Prostate Cancer Using Anti-PSMA Antibody 177Lu-J591: RIT Alone and RIT in Combination with Docetaxel

S. Vallabhajosula, 2007 .

Molecular Imaging of Prostate Cancer: Radiopharmaceuticals for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT)

S. Vallabhajosula, J. Babich, B. Polack, 2018 .

Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of 68Ga3+, 111In3+, 177Lu3+ and 225Ac3.

James M. Kelly, Shankar Vallabhajosula, Alejandro Amor-Coarasa, 2017, Nuclear medicine and biology.

Quantitative SPECT imaging with Lu-177: A physical phantom evaluation

S. Vallabhajosula, J. Osborne, S. Goldsmith, 2012 .

D-SPECT: A new solid state camera for high speed molecular imaging

Sanjiv S. Gambhir, Daniel S. Berman, Shankar Vallabhajosula, 2006 .

Striatal dopamine type 2 receptor availability in anorexia nervosa

S. Vallabhajosula, M. Slifstein, D. Martínez, 2015, Psychiatry Research: Neuroimaging.

18F‐FPEB PET/CT Shows mGluR5 Upregulation in Parkinson's Disease

P. Mozley, S. Vallabhajosula, Yeona Kang, 2018, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).

S. Vallabhajosula, N. Bander, C. Sternberg, 2021 .

Final results of 2-dose fractionation of 177Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).

H. Beltran, S. Vallabhajosula, N. Bander, 2016 .

99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer

S. Vallabhajosula, J. Osborne, S. Tagawa, 2014, The Journal of Nuclear Medicine.

Reduced glucose uptake and Aβ in brain regions with hyperintensities in connected white matter

Henry Rusinek, Y. Li, Mony J. de Leon, 2014, NeuroImage.

Thyroid uptake of liquid versus capsule 131I tracers in hyperthyroid patients treated with liquid 131I.

S. Vallabhajosula, S. Goldsmith, D. Becker, 1999, Thyroid : official journal of the American Thyroid Association.

Cortical Laminar Binding of PET Amyloid and Tau Tracers in Alzheimer Disease

H. Rusinek, M. D. de Leon, S. Vallabhajosula, 2015, The Journal of Nuclear Medicine.

Radiopharmaceuticals in Molecular Imaging

Shankar Vallabhajosula, S. Vallabhajosula, 2014, Encyclopedia of Computational Neuroscience.

Carbon‐11 labeled (±)‐ and (‐)‐ketamine: Synthesis and PET studies in a baboon

S. Vallabhajosula, A. Wolf, J. Fowler, 1989 .

Systemic biodistribution of radioiodinated interleukin-2 in the rat.

S. Vallabhajosula, R. Zappulla, S. Goldsmith, 1989, Journal of biological response modifiers.

The Cell: Structure, Function, and Molecular Biology

S. Vallabhajosula, S. Mustafa, 2006 .

Original Articles TARGETING METASTATIC PROSTATE CANCER WITH RADIOLABELED MONOCLONAL ANTIBODY J591 TO THE EXTRACELLULAR DOMAIN OF PROSTATE SPECIFIC MEMBRANE ANTIGEN

S. Vallabhajosula, N. Bander, M. Milowsky, 2003 .

Phase II Study of Lutetium-177 – Labeled Anti-Prostate-Speci fi c Membrane Antigen Monoclonal Antibody J 591 for Metastatic Castration-Resistant Prostate Cancer

S. Larson, S. Vallabhajosula, N. Bander, 2013 .

177Lu-J591 monoclonal antibody (Lu-J591) therapy in metastatic castrate-resistant prostate cancer (metCRPC): Correlation of antibody-tumor targeting and treatment response

S. Vallabhajosula, N. Bander, S. Tagawa, 2008 .

Imaging Inflammation in a Patient with Epilepsy Due to Focal Cortical Dysplasia

David Silbersweig, Masanori Ichise, Orrin Devinsky, 2013, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

2200 A PHASE 1 PILOT STUDY OF 99MTC-MIP-1404 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT)/CT IMAGING IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY

S. Vallabhajosula, J. Osborne, B. Robinson, 2013 .

A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).

S. Vallabhajosula, N. Bander, C. Sternberg, 2021 .

Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

S. Larson, S. Vallabhajosula, N. Bander, 2013, Clinical Cancer Research.

Tc-99m labeled small-molecule inhibitors of prostate-specific membrane antigen (PSMA): New molecular imaging probes to detect metastatic prostate adenocarcinoma (PC).

S. Vallabhajosula, J. Osborne, S. Tagawa, 2012, Journal of Clinical Oncology.

Pilot Study of Hyperfractionated Dosing of Lutetium-177 – Labeled Antiprostate-Speci ﬁ c Membrane Antigen Monoclonal Antibody J591 ( 177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer

K., S. Vallabhajosula, Scott, 2020 .

Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)

S. Vallabhajosula, N. Bander, M. Morris, 2007 .

PD16-11 COMPARISON OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED RADIONUCLIDE THERAPY (TRT) WITH LUTETIUM-177 ( 177 LU) VIA ANTIBODY J591 VS SMALL MOLECULE LIGAND PSMA-617

S. Vallabhajosula, N. Bander, J. Osborne, 2020 .

Abstract 4696: Non-invasive measurement of prostate-specific membrane antigen (PSMA) expression with radiolabeled J591 imaging: a promising biomarker for PSMA-based radioimmunotherapy.

S. Vallabhajosula, N. Bander, J. Osborne, 2013 .

Evaluation of four radiopharmaceuticals for imaging inflammation in a rabbit model of arthritis

S. Vallabhajosula, S. Goldsmith, C. Palestro, 1996, Annals of nuclear medicine.

Maternal age affects brain metabolism in adult children of mothers affected by Alzheimer's disease

S. Santi, S. Vallabhajosula, L. Mosconi, 2012, Neurobiology of Aging.

Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591.

S. Vallabhajosula, N. Bander, S. Tagawa, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small molecule inhibitors of prostate specific membrane antigen (PSMA) for SPECT: Summary of phase I studies in patients with prostate cancer (PCa)

S. Vallabhajosula, J. Osborne, S. Goldsmith, 2012 .

PSMA targeted SPECT imaging biomarker to detect local and metastatic prostate cancer (PCa): Phase I studies with 99mTc-MIP-1404

S. Vallabhajosula, J. Osborne, S. Tagawa, 2013 .

Targeting metastatic prostate cancer [PCa] in patients with 123I-MIP1072 & 123I-MIP1095

R. Coleman, S. Vallabhajosula, N. Petry, 2009 .

Metastatic Prostate Cancer Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen : 99

S. Vallabhajosula, J. Osborne, S. Tagawa, 2014 .

Development of a Radiolabeled Monoclonal Antibody to Prostate-Specific Membrane Antigen

S. Vallabhajosula, N. Bander, M. Milowsky, 2005 .

Continuation of comprehensive quality control of the itG 68Ge/68Ga generator and production of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for clinical research studies.

James M. Kelly, S. Vallabhajosula, J. Babich, 2017, Nuclear medicine and biology.